Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated Primary Liver Cancer

Exclusion Criteria

• •Patients with other primary cancers;
• •Patients with a severe parenchymal disease and unable to accept ICIs treatment;
• •Patients with a psychiatric disorder and unable to comply with this study;
• •Patients with symptomatic brain metastasis, anticipated complications or cognitive disorders that are associated with brain metastasis;
• •Adverse events related to prior anti-tumor treatment (except for hair loss of any grade) did not return to grade 1 or better;
• •History of cells or organ transplantation;
• •History of hypersensitivity to the drug administered in this study or contrast media for CT and MRI;
• •Patients who accepted hepatic local therapy (including ablation therapy, percutaneous injection of ethanol or acetic acid (PEI/PAI), high-intensity focused ultrasound (HIFU), transarterial chemoembolization (TACE)) within 14 days prior to initiation of the study;
• •Other reasons that the researchers think not suitable for ICIs treatment